Overview
Avalo Therapeutics Q3 net loss misses analyst expectations
Operating expenses rose due to Phase 2 LOTUS trial costs
Completed enrollment for Phase 2 LOTUS trial; data expected mid-2026
Outlook
Avalo expects cash reserves to fund operations into 2028
Topline data from Phase 2 LOTUS trial expected mid-2026
Result Drivers
R&D EXPENSES - Increased R&D expenses driven by Phase 2 LOTUS trial costs
LEADERSHIP EXPANSION - Expanded leadership team with key appointments in business development and HR
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
Miss
-$30.63 mln
-$18.75 mln (8 Analysts)
Q3 Pretax Profit
Miss
-$30.61 mln
-$18.77 mln (7 Analysts)
Q3 Operating Expenses
$19.20 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Avalo Therapeutics Inc is $35.00, about 53% above its November 5 closing price of $16.45
Press Release: ID:nGNX4DRgXz
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
